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Abstract
Background: Spreading effective, guideline-based cardioprotective care quality improvement strategies between
healthcare settings could yield great benefits, particularly in under-resourced contexts. Understanding the diverse
factors facilitating or impeding such guideline implementation could improve cardiovascular care quality and
outcomes for vulnerable patients.
Methods: We sought to identify multi-level factors affecting uptake of cardioprotective care guidelines in
community health centers (CHCs), within a successful trial of cross-setting implementation of an effective
intervention. Quantitative analyses used multivariable logistic regression to examine in-person patient encounters at
10 CHCs from June 2011-May 2014. At these encounters, a point-of-care alert flagged adults with diabetes who
were clinically indicated for, but not currently prescribed, cardioprotective medications. The main outcome measure
was the rate of relevant prescriptions issued within two days of encounters. Qualitative analyses focused on CHC
providers and staff, and, guided by the constant comparative method, were used to enhance understanding of the
factors that influenced this prescribing.
Results: Recommended prescribing occurred at 13–16% of encounters with patients who were indicated for such
prescribing. The odds of this prescribing were higher when the patient was male, had HbA1c ≥7, was previously
prescribed a similar medication, gave diabetes as the chief complaint, saw a mid-level practitioner, or saw their
primary care provider. The odds were lower when the patient was insured, had ≥1 clinic visits in the past year, had
kidney disease, or was prescribed certain other medications. Additional factors were associated with prescribing of
each medication class. Qualitative results both supported and challenged the quantitative findings, illustrating
important tensions involved in guideline-based prescribing. Clinic staff stressed the importance of the provider-
patient relationship in guiding prescribing decisions in the face of competing priorities and care needs, and the
impact of rapidly changing guidelines.
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Conclusions: Diverse factors associated with guideline-concordant prescribing illuminate the complexity of
delivering evidence-based care in CHCs. We present possible strategies for addressing barriers to guideline-based
prescribing.
Clinical trials registration: This trial was registered retrospectively.
Currently Controlled Trials NCT02299791. Retrospectively registered 10 November 2014.
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Background
Spreading effective quality improvement (QI) strategies
across healthcare settings is challenging. We studied such
cross-setting translation using a diabetes care QI interven-
tion, the ‘ALL Initiative,’ or ‘ALL.’ At Kaiser Permanente
(an integrated care system serving insured patients), ALL
substantially improved rates of guideline-concordant
prescribing of cardioprotective statins and angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin II receptor
blockers (ARBs) to patients with diabetes [1]. Through a
cluster-randomized clinical trial (cRCT), we demonstrated
the overall feasibility and effectiveness of translating ALL
into community health centers (CHC) serving socio-
economically vulnerable patients [2]. We then conducted
this mixed-methods assessment to better understand the
multi-level factors affecting cardioprotective prescribing at
CHC encounters.
In the general U.S. population, CVD-related care often
does not adhere closely to care guidelines [3]. Evidence
shows that less than half of individuals at risk of devel-
oping CVD are treated according to guidelines [4, 5],
and rates of appropriate care are especially low in the ra-
cial/ethnic minority [4–6], uninsured [7], and low-
income patient populations [8, 9] served by CHCs. A
few previous studies identified factors that can impact
adoption of guideline-based cardioprotective prescribing
[10]. In a Veterans’ Affairs population, only 8% of clini-
cians intended to act on guideline-based prescribing,
even when alerted to do so [11]. Their reasons included
not being the patient’s primary care provider (PCP), pre-
ferring to wait until another visit, disagreement with the
guidelines, or anticipated patient nonadherence. In other
contexts, guideline-based ACEI/ARB prescribing was
more likely among patients who were male [9] or had
high blood pressure [12], and less likely if there were
clinical contraindications [13]. Other factors precluding
guideline-based prescribing included patient preference
and clinician judgment [13]. Our objective was to con-
tribute to this literature by providing richly described
mixed methods data on the multi-level factors associated
with implementation of guideline-based cardioprotective
prescribing in a context where alerts were provided to
notify CHC clinicians of patients indicated for such
prescribing. Little such research has been conducted in
this important but often neglected setting [14–17].
Methods
We adapted Kaiser Permanente’s successful intervention,
which targets guideline-based cardioprotective prescrib-
ing for patients with diabetes mellitus, through an itera-
tive, stakeholder-driven process involving researchers,
electronic health record (EHR) programmers, and CHC
staff and providers, as previously described [18]. We
then conducted a cluster-randomized pragmatic trial in
11 CHCs in a staggered process with six “early” CHCs
implementing the intervention one year before five “late”
CHCs.
CHCs serve the most vulnerable patients in the United
States, whose CVD prevalence and risk are significantly
higher than in the general population [19]. The study
CHCs were members of OCHIN, Inc., a non-profit
organization that provides health information technol-
ogy, including an EpicCare© electronic health record
(EHR), to CHCs [20, 21]. All OCHIN member clinics
share one instance of the EpicCare EHR with a single
master patient index, managed by OCHIN. The 11 study
CHCs are ambulatory primary care clinics managed by
three Federally Qualified Health Center systems in the
Portland, Oregon metropolitan area. They vary in size
and organizational structure: one is operated by a large
academic medical center; six by an urban county health
department; and four by a non-profit organization pri-
marily serving suburban, Spanish-speaking populations.
The study CHCs were recruited from OCHIN’s mem-
bership, based on their willingness to participate, and
their location in or near Portland, Oregon, to enable rich
qualitative data collection. No sampling was involved.
Quantitative data were extracted from OCHIN’s EHR
database. Verbal consent was obtained from clinic staff
for qualitative data collection. The study was approved
by Kaiser Permanente Northwest’s Institutional Review
Board.
The quantitative analyses include all in-person encoun-
ters between June 2011 and May 2014 at the intervention
CHCs, at which an ALL-related point-of care alert ‘fired,’
and the provider had prescribing privileges. Per the alerts’
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criteria, these were encounters with adult (aged 18–75)
patients with diabetes who were clinically indicated for a
targeted medication according to national guidelines
(Additional file 1: Appendix A) but did not have a pre-
scription within the last year. (The alerts did not fire for
patients with documented contraindicating diagnoses).
We excluded one CHC where the alerts were unintention-
ally deactivated, leaving 10 CHCs in these analyses.
Our ethnographic process evaluation [22] was designed
to understand the intervention and its impact from the
participants’ perspective [23] to gain a rich understanding
of the ‘how’ and ‘why’ behind quantitative results. Over
three years, a two-person qualitative team assessed rele-
vant care team actions and decision-making through
observation of CHC workflows (126 fieldnotes), interviews
and group discussions with CHC staff (42 transcripts),
weekly diaries completed by clinic-based study staff




This retrospective analysis used EHR data from the
24 months following activation of the alerts in the study
CHCs. Since the study involved staggered implementa-
tion (the alerts were activated sequentially in different
CHCs), calendar dates for data collection varied. The
outcome of interest was whether a relevant prescription
was issued within two days of patient encounters in
which a point-of-care alert ‘fired.’ We examined statin
prescribing rates in encounters in which a statin alert
fired (‘statin encounters’), and ACEI/ARB prescribing
rates in encounters in which an ACEI/ARB alert fired
(‘ACEI/ARB encounters’). If both types of alert fired at
one encounter, the encounter was included in both
groups. Patient- and encounter-level independent
variables were selected based on subject matter know-
ledge, previous research, data availability, and qualitative
results.
We conducted descriptive analyses and checked inde-
pendent variables for collinearity, choosing one for in-
clusion in subsequent analyses if indicated (e.g., ethnicity
was highly correlated with language, so we dropped lan-
guage). Since the data included repeated measures (indi-
vidual patients could have multiple encounters in the
data) and dichotomous outcomes, we used general esti-
mating equations with binary outcome and a log link
function [24]. We examined bivariate models for each
outcome-independent variable pair, and interactions
between selected variables (e.g., patient age * sex). Any
variable or interaction significantly associated with the
outcome at α = .10 was included in a multivariable
model. Next, covariates and interaction terms were
systematically removed using backward elimination
(cutoff of α = .05) until a final multivariable model was
specified. Only encounters with complete information
on all covariates were utilized. Sensitivity analyses were
performed to examine the effect of covariance structure
on model fit, and a 1-dependent covariance structure
was selected for the final multivariate models. As the
study CHCs were operated by three service organiza-
tions, all models were adjusted by organization. Statis-
tical analysis was performed using SAS 9.4.
Qualitative
Qualitative analysis was guided by the constant com-
parative method [25, 26], in which inductive conceptual
categories (codes) are identified in a preliminary set of
data; subsequent data is continually compared to those
initial categories to identify commonalities and differ-
ences and confirm or challenge emerging patterns and
interpretations. In this case, one year into the three-year
data collection period, the two-person qualitative team
undertook a process of data immersion, reflection, and
discussion [27] to identify emergent categories (codes) in
the data collected to date. Codes were grounded in the
data, and developed prior to and independent of the
quantitative results. Each of the two researchers then
independently applied these codes to a sample of tran-
scripts, compared and discussed results, and adjusted
code definitions as necessary to ensure agreement; this
cycle was repeated until the coders were confident that
they understood the codes and had applied them con-
sistently. The lead qualitative researcher then used QSR
NVivo software to code all the qualitative data collected
thus far. As additional data was collected and compared
with the initial categories, code definitions were refined
and additional codes added as necessary. Any disagree-
ment or discrepancy was resolved by consensus. Identifi-
cation of patterns in the data (connections between
categories) and our interpretations of these patterns was
informed by our time in the clinics, regular conversa-
tions among the study team, and presentation of prelim-
inary results to clinic leadership for feedback (member
checking) [28]. Qualitative coding was complete before
quantitative analyses were conducted. After statistical
analyses were completed, the qualitative data were used
to better understand the ‘why’ behind the overall inter-
vention outcomes.
Results
Descriptive analyses included 11,588 statin encounters
and 9,887 ACEI/ARB encounters. Only 13.2% of statin
encounters and 15.8% of ACEI/ARB encounters resulted
in an order for an indicated medication within 2 days
(Table 1).
In multivariable regression analyses, after excluding
encounters with incomplete data, the final statin model
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included 11,084 encounters, and the final ACEI/ARB
model included 9,108 encounters. Figure 1 shows the
results of these regression analyses. For most of these
regression analysis results, qualitative data provided rich
explication; see Table 2.
Patient gender
The odds of prescribing indicated statins and/or ACEI/
ARBs were significantly higher in encounters where the
patient was male (versus female). Qualitative data indi-
cated common provider discomfort with giving terato-
genic medications to women of childbearing age; many
providers were more comfortable prescribing to women
at the older end of the childbearing years. Most said they
would prescribe ACEI/ARBs and statins to women of
childbearing age if they felt the patient understood the
risks and was on reliable birth control (variously
defined). A couple of providers felt this decision should
Table 1 Encounter characteristics associated with statin and ACEI/ARB prescribing at in-person office visits at 10 community health
centers in Oregon where the medication(s) was/were clinically indicateda, June 2011 to May 2014
Office visitsb where a statin indicated Office visitsb where an ACEI/ARB was indicated
Number of
encountersc
% with an statin
Rx < = 2 days
p-value Number of
encountersc
% with an ACEI/ARBs
Rx < = 2 days
p-value
Total 11588 (13.2) 9887 (15.8)
Encounters
Diabetes encounterd <.0001 <.0001
# encounters for patient in last year with same provider <.0001 <.0001
0 3114 (14.3) 2669 (21.9)
1-3 4345 (16.8) 3455 (18.4)
> = 4 4129 (8.7) 3763 (9.2)
# encounters for patient in last year at same clinic <.0001 <.0001
0 1186 (22.9) 1091 (37.2)
1-3 4114 (18.4) 3202 (20.5)
> = 4 6288 (8.0) 5594 (9.0)
Diabetes encounterd <.0001 <.0001
No 5082 (6.2) 4388 (8.7)
Ye 6506 (18.7) 5499 (21.5)
Encounter provider type 0.0003 <.0001
Physician/Resident 6810 (12.3) 6256 (13.6)
PA/NP 4778 (14.6) 3631 (19.6)
Encounter provider was PCP? <.0001 <.0001
No 2092 (7.1) 1672 (10.0)
Yes 9257 (14.5) 7988 (16.8)
Missing/Unknown 239 (19.2) 227 (25.6)
Nurse touched chart in encounter? <.0001 0.0007
No 8383 (12.3) 7190 (15.1)
Yes 3205 (15.6) 2697 (17.9)
# non-study alerts fired at encounter 0.5615 0.0046
0 2076 (13.0) 1681 (17.3)
1-2 6376 (13.0) 5650 (14.8)
> = 3 3136 (13.8) 2556 (17.2)
Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blockers; PA Physician’s Assistant, Pcp primary care provider assigned to
patient, NP Nurse Practitioner
aPoint-of-care alert for specified drug class fired at the visit
bOffice visits defined as in-person encounters at a study clinic where the provider was a MD, PA, NP, or resident, and the encounter Evaluation & Management
CPT code was in: 99201-99205; 99212-99215; 99243; 99385-99387; 99395-99397
cVisit counts are not mutually exclusive, e.g., if both types of BPA fired at a visit, the visit is counted in both the statin and ACEI/ARB columns. p-value from chi
square test for independence between characteristic and outcome of Rx < = 2 days
dDiabetes encounter = DM listed as chief complaint or DM listed as the primary Dx for visit, or DM was the first Dx associated with visit
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be the patient’s: “But to not treat you for something we
know you’re at huge risk for just because you might skip
a pill and get pregnant … seems very paternalistic … like
not really giving people the full information, the full
treatment.” Others almost never prescribed these medi-
cations to younger women: “I’m totally uncomfortable
with that. I’m not going to do it.”
Prior prescriptions
The odds of prescribing indicated statins and/or ACEI/
ARBs were significantly higher in encounters in which
the patient had a prior prescription for a medication in
the indicated class (versus not). Qualitative data indi-
cated that many patients with prior prescriptions merely
needed refills. However, providers noted that patients
who had side effects from a prior prescription often
resisted trying another medication in that class, report-
ing, for example: “They just give up and won’t take any-
thing.” Many reported being less likely to encourage
patients with past side effects to try again, anticipating
resistance, and judging that the time was better spent
elsewhere.
Type of provider
The odds of prescribing indicated statins and/or ACEI/
ARBs were significantly higher in encounters in which
the patient was seen by a mid-level practitioner (Nurse
Practitioner (NP) or Physician’s Assistant (PA)), versus a
physician or a resident. Mid-level providers said they
may be more likely to follow care guidelines because
they are “good little soldiers,” fear legal repercussions,
have less training in analyzing evidence, and are less
‘ego-driven’ than doctors. About half of the physicians
thought mid-level providers might follow guidelines bet-
ter because physicians “… feel like we should be able to
practice autonomously.”
Primary care provider
The odds of prescribing indicated statins and/or ACEI/
ARBs were significantly higher in encounters where the
patient was seen by their PCP (versus another provider).
Qualitative findings show that most providers said they
would not start a new preventive medication for
another’s patient, although some indicated they would
welcome such help, and many were willing to refill
another provider’s prescription. Several said they would
prescribe for patients of other PCPs on their team:
“[W]hen we cover amongst our team, [we] have no prob-
lem starting somebody on Lisinopril who should be on
it.” The provider-patient relationship was important; sev-
eral providers said knowledge of the patient affected
when and how they prescribed the indicated medica-
tions. If they knew the patient was motivated, supported,
and likely to be compliant, they were more likely to pre-
scribe. One stated, “I think it really depends on how well
Fig. 1 Adjusted odds ratios, 95% confidence intervals associated with statin and ACEI/ARB prescribing at in-person office encounters at 10 community
health centers in Oregon, at which the medication(s) was/were clinically indicated; June 2011-May 2014. Statin encounters n = 11,084. ACEI/ARB
encounters n = 9,108
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you know your patient … [and] assess your patient's
ability to deal with that stuff.”
Competing needs
The odds of prescribing statins and ACEI/ARBs were
significantly lower when the patient had ≥1 visits to the
same clinic in the past year (versus none, or never seen
at the clinic before). Qualitative data added nuance to
this finding. Many providers said that they adjusted the
care provided to avoid overwhelming patients at a single
or first visit. One said, “… if we load up in the beginning,
a lot of times they just shut down and their adherence
goes into the toilet.” Conversely, a few said they try to
prescribe all necessary medications at a single visit, but
if they meet resistance, they pace introducing new medi-
cations: “I try to do it all in the beginning … if it's not
working, I try to slowly slither them in.” Some scheduled
additional visits, hoping to quickly catch the patient up
on needed care. Others waited to prescribe cardioprotec-
tive medications until the patient was reliably taking
blood sugar medications, and/or had controlled HbA1c;
one noted: “… some patients … it takes me years to get
them on … [cardioprotective] meds.” Patient preference
(or provider perception of it) also influenced prescribing
strategies; one provider noted, “… some people just get
totally overwhelmed. Other people feel like, okay, let's
treat everything. Let's get started. I don’t want to die.”
The odds of prescribing indicated statins and/or ACEI/
ARBs were significantly higher in encounters in which
the patient’s chief complaint was diabetes (versus
another complaint). Qualitative data showed that pro-
viders rarely have time for diabetes-related preventive
Table 2 Selected excerpts from qualitative data by theme
Theme Excerpts
Patient gender “And the statins, I was never really comfortable with the under forties. We have a lot of thirty-four year old women that you guys
want me to put on an ACE or a statin. And I’m just not going to do it, because they're going to end up pregnant on two class X
medications.” (MD)
“Well, I talk to them about birth control, and if they’re on. A lot of them have had their tubes tied, so then I, you know, go ahead
and prescribe it if they’re willing to take it. And then some of them are pretty unreliable with their methods, or questionable. So then
I, you know, talk to them, try to get them on more reliable birth control. And then … if they’re willing to do that, then, you know,
I’m willing to do it.” (MD)
Prior prescriptions “I find that a fair number of my patients do have side effects to Statins and we just can’t find one that doesn’t cause them
myalgias.” (NP)
“I mean, it varies. But yeah, usually they [patient] don’t want to try another one [if have side effects].” (NP)
Provider type “… I think historically NPs are really good at following guidelines. … Ultimately it’s going to be like, okay, well, if the … Board
of Physicians has decided that this is what should be done, I’m probably going to follow it. I think there’s something about the
hierarchy of education level and training.” (NP)
“… I’ve practiced long enough to have known lots of MDs who are guideline resistant. You know, in terms of telling me how
I have to practice kind of thing.” (MD)
Primary care provider "I’m not going to manage somebody’s diabetic. If you’re a diabetic you need a home.” (MD)
Competing needs “… these are fifteen minute appointments. When someone has a migraine you’re not going to be like, so enough about the
migraine. Like what’s up with your insulin, you know? So I think that so many of our patients come here for acute pain needs,
that this stuff is all overlooked.” (RN)
“If I have a new diabetic I talk to them … [about] the fact that there are all sorts of recommendations about medications that
we use to treat not only the blood sugar, but also to help prevent complications of it. And if we put you on every medicine that’s
recommended you’d walk out of here and you’d have a … shopping bag full. And I say, but that’s not where we’re going to start.
… I do it piecemeal. It’s so overwhelming otherwise, I think.” (MD)
Concurrent medications … shared that her Russian patients do not like pills as a general rule and are highly resistant to multiple meds. In their culture,
they have an old saying: "You treat one and kill the other one…. [RN] told me that this thinking is pervasive in their culture, so
many patients refuse preventive meds completely … this is a real problem for her patients who … are already taking an anti-
glycemic agent … will refuse any other meds because one should be enough. (observation field note)
Wonders if there are any meds we can suspend or discontinue, she is feeling burdened with the amount of pill she takes …
PLAN: continue ACEi … suspend statin today to reduce pill burden. (PA encounter notes from patient chart)
Changing guidelines “Which is was a little unclear to me around, like if I have like a nineteen year old, you know, should I put them on a statin? And
then that changed even more recently with the AHA Guidelines. And so to me it felt like a moving target.” (Resident)
“[W]hat was the age cut off again? You know, it's like those things change over time. Was it forty, was it fifty? … how many
other risks do they have to have before I put them on this medicine, you know?” (RN)
Patient age "And you're twenty-seven years old, and I'm going to make you take a bunch of pills for the rest of your life. It's hard … I feel
much better about doing it for middle-aged people with bad diabetes." (NP)
“I’m not convinced that by putting someone on a tiny dose of an ACE it’s going to really reduce their cardiovascular risk if
they’ve only had diabetes for two years and they’re less than fifty.” (MD)
Abbreviations: MD Medical Doctor, NP Nurse Practitioner, RN Registered Nurse
Gold et al. BMC Health Services Research  (2017) 17:253 Page 6 of 13
care at visits where other medical needs are more acute/
important to the patient. One provider said, “People who
come in a lot are often in for chronic pain. We almost
never get beyond that.”
Concurrent medications
The odds of prescribing both statins and ACEI/ARBs
were significantly lower when the patient had an active
prescription for insulin, narcotic analgesics, CVD medi-
cations, and/or psychotherapeutics (versus not). The
odds of statin prescribing were lower if the patient had a
prescription for a non-insulin antihyperglycemic. As de-
scribed above, providers struggled to prioritize patients’
multiple needs, and had concerns about overwhelming
patients with medications. One stated: “People who have
limited resources and who are … having a hard enough
time taking care of… one thing, you give them another
thing, and bloop, you lose something.” Patients some-
times refused additional medications, particularly those
intended to prevent, rather than treat, illness.
Changing guidelines
The odds of prescribing indicated statins and/or ACEI/
ARBs were significantly higher in encounters in which
the patient had HbA1c of ≥7 (versus <7), and odds of
ACEI/ARB prescribing were higher for patients with
blood pressure of ≥120/80 (versus <120/80). This oc-
curred even though the intervention was based on
current, evidence-based guidelines which recommended
prescribing ACEI/ARBs and statins to all patients with
diabetes based on age and comorbidities, regardless of
blood pressure or HbA1c values – a substantial change
from prior recommendations. Qualitative data showed
that although most providers cautiously supported the
shift from prescribing statins/ACEI/ARBs as treatment
(based on lab values) to prescribing preventively against
future cardiovascular disease (CVD), comfort with doing
so for patients with ‘normal’ or borderline labs varied.
This was particularly true for patients already on mul-
tiple medications, concurring with providers’ previously
described concern about overwhelming patients. Pro-
viders and staff said it could be difficult to change from
the customary focus on HbA1c to prioritize cardiovascu-
lar health; and, as above, some chose to wait to prescribe
cardioprotective medications until the patient’s HbA1c
was controlled. An RN noted: “We just … autopilot to a
more traditional diabetic stance, ignoring the cardiovas-
cular aspect of it.” Furthermore, changing guidelines
bred mistrust; one provider said, “You stay in medicine
long enough and everybody wants to solve everything
with X. And then, twenty years later you find out, oh,
that didn’t work.”
Patient age
Older age (>40 versus 18-39 years) was associated with
higher odds of statin prescribing. This, too, appeared to
be related to changing care guidelines. Providers often
noted discomfort with putting younger patients on life-
long medications with potential side effects, especially
statins. One said: “When the 20-year-old doesn’t want to
go on the statin [I say] okay, just work on your blood
sugar control.” Some felt the evidence for prescribing
statins to younger patients was unclear, and were uncon-
vinced that the benefits of prescribing statins to younger
people outweighed the risks; as a result, providers often
did, as one noted, “…the thing that leads to less
intervention.”
Other factors significantly associated with guideline-
concordant prescribing in quantitative results (for which
there was little or no qualitative data) were more clearly
based on clinical factors. Statin prescribing was signifi-
cantly lower for patients with documented liver disease,
and prescribing of either medication was lower for
patients with kidney disease. ACEI/ARB prescribing was
lower for patients with known CVD; higher odds of
statin prescribing were seen among patients with low
density lipoprotein (LDL) ≥100 (versus <100), and higher
odds of ACEI/ARB prescribing among those with BMI
of ≥25 (versus <25).
One other factor associated with guideline-based pre-
scribing was patient’s insurance status, for which little
qualitative data existed. However, the odds of prescribing
for both statins and ACEI/ARBs were significantly lower
when the patient was insured (versus uninsured).
Role of automated alerts
Though we could not quantify how often the EHR-based
alerts were read, reactions to the alerts were consistently
mentioned in the qualitative data. One common theme
was that past EHR alerts (unrelated to the study) were
inaccurate, creating an ingrained mistrust of all alerts.
One nurse noted, “It’s not about the tool, it’s about the
culture history.” We also heard concerns specific to the
study-related alerts; providers sometimes thought these
alerts were wrong when data elements used by the
underlying algorithm were inaccurate in the chart (e.g.,
outdated prescriptions), or the algorithm specifications
were not understood (e.g., prescriptions written >1 year
previously were considered inactive). One provider
wrote, “I don’t want the [alert] to fire and it makes me
irritable and more likely to ignore it. It needs to learn to
read. I write prescriptions for 2 year [refills] because I
DO want folks to keep taking their meds. Grr.” Percep-
tions varied; some providers did not notice the alerts,
while others said the alerts were useful reminders and
improved overall awareness. One noted “I like the [alert]
because it reminds me.” Perceptions could change; some
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said the alerts were effective initially, but after updating
their patients’ prescriptions, they were less useful. Con-
versely, others grew to increasingly rely on the alerts as
EHR-based alerts overall were seen as more trustworthy,
as they became convinced the study alerts were appro-
priately tested, and/or due to mounting evidence behind
the recommendations.
Discussion
Even in the context of an intervention demonstrated to
be effective through a cRCT [2], prescribing occurred at
only 13–16% of encounters in which the patient was
clinically indicated for an ACEI/ARB/statin (Table 2). In
multivariate models, patients with diabetes were more
likely to receive guideline-concordant cardioprotective
prescriptions if they were male, older, or uninsured, had
been previously prescribed a medication in the indicated
class, were seen by an NP or PA, were seen by their own
PCP, had poorly controlled A1c/BP, had few recent visits,
had few other current prescriptions, or if diabetes was
the chief complaint at that encounter (Tables 3, 4). Our
findings generally align with previous research on factors
predicting guideline-based CVD care, as outlined in the
Introduction [10–13]. Like others [10], we found that
guideline-based prescribing was low overall. At encoun-
ters with automated alerts, guideline-based prescribing
was more likely if the patient was male [9], saw their
regular provider, and had no contraindicating comorbid-
ities [11, 13]. Prescribing was also impacted by changing
care guidelines [11], and by patient preference and/or
clinician judgement about what a given patient could or
would take on at a given visit [11, 13]. Differing from
some past research [9], we found that past utilization
was associated with prescribing. Our results add to this
literature by presenting mixed methods findings on
multi-level factors associated with provision of
guideline-based CVD care, in the CHC setting, and in
the context of an overall successful QI intervention in-
volving automated reminder alerts. We also identified
that mid-level providers were more adherent to prescrib-
ing guidelines than were physicians.
The diverse factors associated with guideline-concordant
cardioprotective prescribing illuminate the complexity of
delivering evidence-based care, and the challenges associ-
ated with implementing up-to-date clinical guidelines, espe-
cially in CHCs. We discuss this complexity below, and
present a few suggestions for how healthcare providers
could address some of these barriers to guideline-
concordant care. (We recognize that these approaches may
not be feasible in some care settings, but present them as
potential starting place for further discussion and inquiry.
While it is beyond the scope of this paper to do more than
make cursory recommendations, we recommend that
further research be conducted on best practices for imple-
menting the kinds of change suggested below.)
The CHC teams serving diabetic patients with mul-
tiple needs sought to avoid overwhelming patients, while
giving all necessary care during the visit. This tension
underlies the complexity in some of our results. Multiple
needs necessitated prioritization, so CVD prevention
guidelines were often secondary to other concerns, even
in diabetes-focused visits. The finding that the medica-
tions were more often prescribed for patients not
recently seen contradicts the qualitative results on pro-
viders’ preference for phasing in medications, and illus-
trates this dilemma. Patients seen more frequently often
have multiple needs, pushing cardioprotective care lower
on the list. Conversely, if patients come in infrequently,
providers might seek to address as many needs as
possible while they have the opportunity.
Since guideline-based prescribing for patients with dia-
betes occurs most often at diabetes-focused encounters,
longer or more frequent diabetes-specific visits might
enable the provision of more recommended care compo-
nents. Alternative care delivery models (e.g., group visits,
virtual visits, or appointments with care managers, clin-
ical pharmacists, nurses, or mid-level staff, in addition to
visits with clinicians) could facilitate patients receiving
all indicated care. For patients who present with multiple
complaints, additional workflow changes (e.g., follow-up
phone calls to address missed needs) may also support
guideline implementation. Guideline-concordant prescrib-
ing was also more likely at encounters where the patient
saw their own PCP. Addressing this constraint might in-
volve clinics ensuring that patients see their PCP, enabling
real-time communication between the PCP and the pro-
vider seeing the patient, or other mechanisms to support
providers prescribing to patients who are not ‘theirs.’ This
result reinforces the importance of having continuity of
care with a primary care provider.
Another theme involved uptake of new guidelines. The
intervention under study was based on guidelines which
substantially differed from previous guidelines, in that
they recommended cardioprotective prescribing to
younger patients, and moved away from prescribing
based on lab values. Yet our results show that patient
age and lab values were significantly associated with pre-
scribing, perhaps because of providers’ unfamiliarity
with, and/or reluctance to adopt, the new recommenda-
tions. Providers noted difficulty with moving diabetes
care away from a focus on HbA1c and treatment, toward
more emphasis on CVD prevention. The alerts factored
in patient LDL when determining the need for a statin
prescription, based on recommendations current at the
time, and higher LDL was associated with statin pre-
scribing. Nevertheless, providers reported discomfort
with prescribing to patients with borderline lab results
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Table 3 Patient characteristics associated with statin and ACEI/ARB prescribing at in-person office visits at 10 community health
centers in Oregon where the medication(s) was/were clinically indicateda, June 2011 to May 2014
Office visitsb where a statin indicated Office visitsb where an ACEI/ARB was indicated
Number of
encountersc
% with an statin
Rx < = 2 days
p-value Number of
encountersc
% with an ACEI/ARBs
Rx < = 2 days
p-value
Total 11588 (13.2) 9887 (15.8)
Patient characteristics
Sex <.0001 <.0001
Male 4198 (15.7) 3819 (17.9)
Female 7390 (11.8) 6068 (14.5)
Age <.0001 0.0607
18–39 1582 (12.2) 747 (17.9)
40–54 3060 (15.5) 2473 (16.7)
55–75 6946 (12.5) 6667 (15.3)
Race/ethnicity <.0001 <.0001
Hispanic 3721 (17.7) 2714 (22.2)
Non-Hispanic White 5460 (10.8) 5035 (12.5)
Non-Hispanic Other 2298 (11.7) 2032 (15.4)
Missing/Unknown 109 (13.8) 106 (20.8)
Language <.0001 <.0001
English 6918 (10.7) 6016 (13.0)
Spanish 3303 (18.3) 2401 (23.1)
Other 1321 (13.6) 1435 (15.4)
Missing/Unknown 46 (10.9) 35 (20.0)
% of Federal Poverty Level at encounter 0.0293 0.2398
< 100% 8568 (12.9) 7294 (15.5)
100–199% 2177 (13.1) 1888 (16.3)
> = 200% 751 (16.8) 639 (17.8)
Missing/Unknown 92 (12.0) 66 (21.2)
Insurance at encounter <.0001 <.0001
Uninsured 3817 (18.2) 2542 (26.1)
Insured 7759 (10.8) 7330 (12.3)
Missing/Unknown 12 - 15 -
Patient smoking status 0.042 <.0001
Not current smoker 8917 (13.6) 7448 (16.7)
Current smoker 2631 (11.8) 2403 (12.6)
Missing/Unknown 40 (17.5) 36 (47.2)
Patient has active diagnosis of CVD 0.0015 <.0001
No CVD 9984 (13.6) 7813 (17.6)
Has CVD 1604 (10.7) 2074 (9.2)
Patient has active diagnosis of HTN 0.1494 0.3498
No HTN 5316 (13.7) 4026 (15.4)
Has HTN 6272 (12.8) 5861 (16.1)
Patient has active diagnosis of liver disease <.0001 <.0001
No liver disease 9946 (13.9) 8572 (16.5)
Has liver disease 1642 (9.1) 1315 (11.3)
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(e.g., LDL of 101, when the guidelines recommended
statins if LDL >100). More recent guidelines de-
emphasized LDL when prescribing statins for patients
with diabetes; implementing this change may involve
similar challenges. This illustrates another tension in the
implementation of evidence-based care: although guide-
lines should be updated to reflect current knowledge,
rapidly changing guidelines can create mistrust.
Addressing this issue may require strategies for
presenting new evidence at the point of care, such as hy-
perlinks to information about why the guideline changed
or relevant clinical guidelines within care alerts. Another
approach might involve identifying clinic champions
tasked with (and given time for) presenting new clinical
guidelines to their colleagues. In some cases, providers’
hesitancy to adhere to guidelines may stem from the fact
that care guidelines are based on aggregate, population-
level data. Though appropriate for most patients, such
data cannot speak to each patient’s needs, creating an-
other tension as providers strive to provide care that is
guideline-based and individualized/‘patient-centric.’ This
might be ameliorated if guidelines were presented as
guides, not dictates, with clinical judgment still consid-
ered best practice, or if related alerts included functions
allowing providers to note when guidelines are inappro-
priate for a given patient [29, 30].
Provider ambivalence about automated alerts almost
certainly helps explain why indicated prescriptions were
not issued even though alerts ‘fired’ at all encounters an-
alyzed here. Here, though the alerts were carefully vetted
with various stakeholders before implementation, some
post-roll-out inaccuracies were identified. For example,
in some cases relevant data (e.g., external prescriptions)
was entered into the EHR in a manner inaccessible to
the underlying algorithm, yielding false alerts. Such inac-
curacies were addressed whenever possible, but a tech-
nical solution was not always feasible. This likely
contributed to provider mistrust of the alerts. Further-
more, while automated alerts can improve prescribing
behaviors [31–33], they are often overridden, ‘alert
fatigue’ is common, and providers often find them irrele-
vant [31, 34–39]. Alerts may have more impact when
Table 3 Patient characteristics associated with statin and ACEI/ARB prescribing at in-person office visits at 10 community health
centers in Oregon where the medication(s) was/were clinically indicateda, June 2011 to May 2014 (Continued)
Patient has active diagnosis of kidney disease <.0001 <.0001
No kidney disease 10759 (13.6) 8614 (17.3)
Has kidney disease 829 (8.1) 1273 (6.3)
BMI 0.2842 0.0009
< 25 1266 (13.8) 1333 (12.5)
> = 25 9914 (13.2) 8251 (16.3)
Missing/Unknown 408 (10.8) 303 (18.8)
BP control 0.1188 <.0001
< 120/80 3174 (12.4) 2834 (9.4)
120/80 to 139/89 6375 (13.1) 5291 (15.2)
140/90 to 159/99 1702 (14.7) 1459 (26.6)
> = 160/100 334 (15.3) 301 (35.5)
Missing/Unknown 3 (33.3) 2 -
HbA1c control <.0001 <.0001
< 7 5115 (10.3) 4398 (12.8)
> = 7 6197 (15.7) 5192 (18.4)
Missing/Unknown 276 (11.6) 297 (16.5)
LDL control <.0001 <.0001
< =100 or missing 4744 (9.6) 5867 (14.3)
100 to 129 4163 (13.7) 2194 (18.0)
> = 130 2681 (18.9) 1826 (18.1)
Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blockers, BMI Body Mass Index; BP blood pressure, CVD cardiovascular
disease, HbA1c glycated hemoglobin, HTN hypertension, LDL-low-density lipoproteins, Rx prescription
aPoint-of-care alert for specified drug class fired at the visit
bOffice visits defined as in-person encounters at a study clinic where the provider was a MD, PA, NP, or resident, and the encounter Evaluation & Management
CPT code was in: 99201-99205; 99212-99215; 99243; 99385-99387; 99395-99397
cVisit counts are not mutually exclusive, e.g., if both types of BPA fired at a visit, the visit is counted in both the statin and ACEI/ARB columns. p-value from chi
square test for independence between characteristic and outcome of Rx < = 2 days
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they target mid-level clinical staff, are more sensitive
(i.e., fire in fewer cases) [36], and include explanations
for the alert’s advice [29]. Another consideration here is
that the alerts were just one aspect of an intervention
which also included staff trainings and education, exam
room posters, and in some clinics, revised care stan-
dards. Our alerts were designed to be easy to ignore, if
desired; improving EHRs’ visual cues might help.
Research is needed on how to maximize alerts’ impact
on provider behaviors [32], e.g., which implementation
strategies [40] best support uptake of new guidelines
[41–46] and which are needed in combination with
alerts to optimally support guideline-based care.
Limitations
We sought to identify the multi-level factors affecting
prescribing at encounters in which alerts fired, but were
unable to assess whether providers actually looked at the
alerts. This limits our ability to assess the alerts’ impact.
Furthermore, our ability to accurately measure nurse
involvement in encounters was limited, reducing our
ability to assess whether nurse involvement affected
outcomes.
Conclusion
‘Translating’ effective QI strategies into CHCs serving
vulnerable populations could yield great benefits, but as
our results show, many factors impact CHCs’ ability to
implement care guidelines. Understanding these factors
is a critical step towards addressing barriers to imple-
menting guideline-based care. This study adds to the
literature on factors affecting guideline implementation
by examining and bringing to light multi-level factors
associated with guideline-based care in CHCs in the
Table 4 Patient prescription history associated with statin and ACEI/ARB prescribing at in-person office visits at 10 community health
centers in Oregon where the medication(s) was/were clinically indicateda, June 2011 to May 2014
Office visitsb where a statin indicated Office visitsb where an ACEI/ARB was indicated
Number of
encountersc
% with an statin
Rx < = 2 days
p-value Number of
encountersc
% with an ACEI/ARBs
Rx < = 2 days
p-value
Total 11588 (13.2) 9887 (15.8)
Patient prescription history
Patient previously had prescription
for indicated drug
<.0001 <.0001
No 6761 (10.9) 2898 (18.5)
Yes 4827 (16.5) 6989 (14.8)
Patient has activedprescription for insulin
No 8682 (14.7) <.0001 7075 (18.7) <.0001
Yes 2906 (8.7) 2812 (8.7)
Patient has activedprescription for
non-insulin anti-hyperglycemic meds
<.0001 <.0001
No 5639 (15.5) 4914 (18.5)
Yes 5949 (11.1) 4973 (13.2)
Patient has activedprescription for narcotic <.0001 <.0001
No 9422 (14.7) 7805 (18.1)
Yes 2166 (6.7) 2082 (7.3)
Patient has activedprescription for CVD meds <.0001 <.0001
No 8374 (15.4) 6553 (19.5)
Yes 3214 (7.6) 3334 (8.7)
Patient has activedprescription for
psychotherapeutic meds
<.0001 <.0001
No 7541 (16.1) 5996 (20.4)
Yes 4047 (7.9) 3891 (8.8)
Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blockers, CVD cardiovascular disease; Rx referral
aPoint-of-care alert for specified drug class fired at the visit
bOffice visits defined as in-person encounters at a study clinic where the provider was a MD, PA, NP, or resident, and the encounter Evaluation & Management
CPT code was in: 99201-99205; 99212-99215; 99243; 99385-99387; 99395-99397
cVisit counts are not mutually exclusive e.g. if both types of BPA fired at a visit, the visit is counted in both the statin and ACEI/ARB columns. p-value from chi
square test for independence between characteristic and outcome of Rx < = 2 days
dRx ordered < date of the visit and end date of order is null or > date of visit
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context of an overall successful QI intervention. Our
mixed-methods approach yielded rich insights into these
factors and illuminated the complexities inherent to
helping CHCs stay up to date on clinical innovations.
Our findings indicate the need for further research on
effective methods for supporting such practice change.
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